Commercial Pharmaceutical Analytics Market Size, Share, and Industry Analysis, By Type (Predictive Analytics, Descriptive Analytics, and Others), By Offering (Software and Services), By Application (Pharmaceutical Marketing, Drug Distribution and Sales, Supply Chain Optimization, and Others), By End-user (Pharmaceutical Companies and Others), and Regional Forecast, 2025-2032

The global commercial pharmaceutical analytics market is witnessing significant growth due to critical factors such as rising drug approvals, competitive pressures, an expanding customer base, and increased OTC sales. Commercial pharmaceutical analytics enhances decision-making capabilities, which is driving its demand and contributing to market growth.

• For instance, according to an article published by NCBI in March 2021, pharmaceutical consumption witnessed significant growth worldwide, driven by a growing need for drugs to treat age-related and chronic diseases. This demands the use of commercial pharmaceutical analytics among pharmaceutical companies to enhance decision-making, which is projected to boost market growth.

Commercial Pharmaceutical Analytics Market Driver

Increasing Drug Development and Approvals to Boost Market Growth

The surge in the development and approval of new drugs is a significant factor supporting the demand for commercial pharmaceutical analytics. The launch of new products by pharmaceutical companies is increasing the need for sophisticated analytics to manage marketing and sales effectively. This is expected to contribute substantially to the market growth over the forthcoming years.

• For instance, according to an article published by BioMed Central Ltd, scientific advances have stimulated drug discovery in the infectious disease space over the past few years due to increased investments from prominent stakeholders and collaborative drug discovery efforts. This is anticipated to boost the demand for commercial pharmaceutical analytics, which will drive market growth.

Download Free sample to learn more about this report.

In 2022, Germany topped for 15.0% export of pharmaceutical products, and on the other hand, the U.S. was the top importer of pharmaceutical products, with a value of USD 168.0 billion in 2022.

Commercial Pharmaceutical Analytics Market Restraint

Data Fragmentation and Integration Issues May Hamper the Market Growth

Despite the high potential of commercial pharmaceutical analytics, it faces significant obstacles, including the fragmentation of data sources across various platforms and departments within pharmaceutical companies. Several pharmaceutical organizations struggle to integrate these disparate data sets, which leads to inefficiencies in data analysis and decision-making processes, hampering the market growth.

• For instance, as per an article published by Straive in September 2024, common obstacles such as lack of data integration, fragmented data sources, and resistance to change within organizations may pose significant challenges in decision-making, which may hamper market growth.

Commercial Pharmaceutical Analytics Market Opportunity

Increasing Sales of Over-the-Counter (OTC) Medications May Spur Market Expansion

In recent years, the increasing sales volume of OTC medications has played a crucial role in driving the demand for commercial pharmaceutical analytics. Companies producing these products leverage analytics to improve sales strategies, with consumers spending significant amounts on OTC drugs annually. Such a scenario is projected to fuel the market expansion in the near future.

• For instance, according to an article published by NCBI in May 2021, there has been a surge in the use of over-the-counter (OTC) drugs in recent years, which may increase the demand for commercial pharmaceutical analytics software and services to improve marketing and sales strategies, contributing to the market expansion.

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Technological Advancements in Commercial Pharmaceutical Analytics
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• New Product Launches, By Key Players
• Impact of COVID-19 on the Market

Analysis by Type

On the basis of type, the market is divided into predictive analytics, descriptive analytics, and others.

The predictive analytics segment is expected to hold a major share of the global market. The segment growth can be attributed to its increasing utilization in the pharmaceutical sector due to its accuracy in making future predictions about trends and possible glitches. Moreover, the competition among pharmaceutical companies to stay ahead and improve product sales is projected to boost the segment growth.

• For instance, according to data published by XcelPros in August 2020, around 93.0% of healthcare executives stated that predictive analytics is crucial to their future business planning. This is expected to propel the segment growth during the projection period.

Analysis by Offering

Based on offering, the market is subdivided into software and services.

The software segment is expected to hold a substantial share of the global market. The segment growth can be attributed to the increasing demand for implementing commercial pharmaceutical analytics software by the commercial teams of pharmaceutical companies across the globe.

• For instance, according to an article published by MedCity News in March 2024, pharmaceutical companies' commercial teams are increasingly seeking enhanced data analytics and business insights. They are prepared to invest more resources to achieve this.

Analysis by Application

Based on application, the market is divided into pharmaceutical marketing, drug distribution and sales, supply chain optimization, and others.

The drug distribution and sales segment is expected to grow at a substantial CAGR during the forecast period. The segment growth can be attributed to the rising investments by pharmaceutical companies in marketing and market research to predict future trends and enhance their decision-making capabilities.

• For instance, according to data published by InData Labs in December 2021, pharma sales can have a positive impact through B2B lead and growth opportunities through the use of predictive analytics driven by significant investments by pharma companies in market research and marketing. This is projected to boost the segment growth over the coming years.

Analysis by End-user

Based on end-user, the market is categorized into pharmaceutical companies and others.

The pharmaceutical companies segment is expected to hold the largest share of the global market during the forecast period. The segment growth can be attributed to the increasing number of pharmaceutical companies across the globe. Commercial pharmaceutical analytics software enables these firms to develop drugs, develop marketing strategies, and optimize sales, propelling their demand among pharmaceutical companies.

• For instance, according to data published by the State Council of the People's Republic of China in November 2023, the country has over 10,000 significant pharmaceutical industrial enterprises, ensuring the nation's high capacity to provide medical supplies. These firms may leverage commercial analytics to enhance operational efficiency and market penetration of their products, boosting the segment growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global commercial pharmaceutical analytics market in 2023. The regional growth is attributed to the increasing focus of companies on optimizing commercial strategies in the pharmaceutical sector to support decision-making.

• For instance, in December 2022, Clarivate expanded its real-world data and analytics solutions by incorporating U.S. specialty pharmacy claims data, enhancing insights into high-cost medications for chronic and rare diseases. This new dataset is expected to allow researchers to analyze drug uptake, patient journeys, and adherence patterns, ultimately supporting evidence-based decision-making in life sciences and driving regional market growth.

Europe is the second-largest market based on the demand for commercial pharmaceutical analytics software and services. The growth is attributed to the high investment of regional pharmaceutical companies in the integration of artificial intelligence solutions and predictive analytical tools for building a strong business future.

The Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to the significant expansion in the pharmaceutical sector of key countries such as China and India. This is projected to fuel the demand for the incorporation of commercial analytics solutions.

• For instance, in September 2024, CRISIL Ratings projected an 8.0-10.0% revenue growth for the pharmaceutical sector this fiscal year, driven by strong exports and consistent domestic demand. Such a scenario is anticipated to boost the incorporation of commercial analytical tools, driving market growth over the coming years.

Key Players Covered

The global commercial pharmaceutical analytics market is fragmented, with many companies offering various treatment products.

The report includes the profiles of the following key players:

• Medidata (U.S.)
• SAS Institute Inc. (U.S.)
• Tellius, Inc. (U.S.)
• Aspen Technology Inc (U.S.)
• Trinity (U.S.)
• Genpact (U.S.)
• Arcadia Solutions, LLC. (U.S.)
• Straive (Singapore)

Key Industry Developments

• In September 2024, Pfizer Inc. launched the Analytics Gateway, its first-ever dedicated commercial analytics center in India, to enhance the reach of its medicines to more patients in India and globally.
• In November 2023, Straive acquired Gramener, an award-winning, design-led data science company, to enhance data, analytics, and AI capabilities.